FOLR2 and breast carcinoma: Consequently, with its targeting of both the FRB and the kinase domains of mTOR, RapaLink-1 has demonstrated the ability to target breast cancer cells with somatic mutations in mTOR, FRB, or the kinase domain, which typically confer drug resistance [54].